An observational study in Cardiogenic Shock, Postresuscitation Disease and Septic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Circulatory shocks are responsible for one third of intensive care unit (ICU) admissions (20,000 patients per year in France) and are associated with 40% mortality [1,2]. Vascular hyperpermeability (also called vascular leakage) is a major feature of circulatory failure. During systemic inflammatory response syndrome (SIRS), massive vascular leakage affects macro and micro-circulation, and participates in the development of multiple organ failure [1,3]. Accordingly, fluid balance (the difference between fluid input and output) correlates independently with mortality during both septic and cardiogenic shock [4-7] and controlling capillary leakage was highly beneficial in numerous animal models of circulatory failure [8-10]. However, the determinants of vascular leakage remain poorly understood in humans.
The purpose of this study is to evaluate the link between circulatory levels of several proteins and the level of vascular leakage, in three distinct types of circulatory shocks.
26 studies on the registry are indexed under Post-Cardiac Arrest Syndrome; 9 are open to participants now.
Browse Post-Cardiac Arrest Syndrome studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.
Patient with one of the circulatory failures described below:
Cardiogenic shock:
Post-resuscitation syndrome:
Septic shock:
Exclusion Criteria:
All patients hospitalized in ICU with a circulatory failure due to septic shock, cardiogenic shock, or post-resuscitation syndrome.
Fluid balance from Day 0 to day 3
(ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,...)
Time frame: Between Day 0 and Day 3
Fluid balance
(ml/kg of initial body weight). The fluid balance, routinely monitored in ICU, represents fluid intakes (perfusion, oral intakes,..) - fluid losses (diuresis, diarrhea,...)
Time frame: Day 1, Day 3, Day 7, Day 14
Extra-vascular lung water index
Extra-vascular lung water index (EVLWi, ml/kg) and pulmonary vascular permeability index measured by transpulmonary thermodilution at corresponding time-points
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Serum albuminemia
g/L
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Serum lactatemia
mmoles/L
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Arterial PaO2
(mmHg)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Circulating cytokine inflammatory profile IL-33
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Circulating cytokine inflammatory profile TNF-alpha
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Circulating cytokine inflammatory profile IL-6
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Circulating cytokine inflammatory profile IL-1
(pg/ml)
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
SOFA score
Association between circulating candidate proteins, the immune-inflammatory profile of the patients and SOFA score
Time frame: Day 0, Day 1, Day 3, Day 7, Day 14
Catecholamine-free days
Number of days alive without receiving any catecholamine
Time frame: Day 0 to Day 7, Day 30
Ventilatory-free days
Number of days alive without receiving any machenical ventilation, invasive or non-invasive
Time frame: Day 0 to Day 7, Day 30
Renal replacement therapy-free
Number of days alive without receiving any renal replacement therapy
Time frame: Day 0 to Day 7, Day 30
Mortality
Time frame: Day 30
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris